Pfizer (NYSE:PFE) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Pfizer (NYSE:PFE) in a research report sent to investors on Monday, Benzinga reports. Cantor Fitzgerald currently has a $45.00 target price on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. StockNews.com upgraded Pfizer from a hold rating to a buy rating in a research report on Thursday, August 1st. Daiwa Capital Markets raised shares of Pfizer from a neutral rating to an outperform rating and upped their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an equal weight rating in a report on Wednesday, July 31st. Wells Fargo & Company upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an equal weight rating in a research note on Wednesday, July 31st. Finally, Daiwa America upgraded shares of Pfizer from a moderate buy rating to a strong-buy rating in a research note on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer has an average rating of Moderate Buy and a consensus target price of $34.54.

Pfizer Trading Down 0.3 %

Shares of PFE stock opened at $29.64 on Monday. The firm has a fifty day moving average of $29.16 and a 200-day moving average of $28.09. The stock has a market cap of $167.96 billion, a price-to-earnings ratio of -494.00, a P/E/G ratio of 1.00 and a beta of 0.68. Pfizer has a 52-week low of $25.20 and a 52-week high of $34.62. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.67 earnings per share. On average, equities research analysts forecast that Pfizer will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were paid a $0.42 dividend. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.67%. Pfizer’s dividend payout ratio (DPR) is currently -2,800.00%.

Hedge Funds Weigh In On Pfizer

Several large investors have recently made changes to their positions in the company. Cantor Fitzgerald Investment Advisors L.P. bought a new position in shares of Pfizer in the 4th quarter valued at about $16,166,000. LGT Group Foundation lifted its holdings in Pfizer by 2.5% in the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after buying an additional 18,274 shares during the period. First Heartland Consultants Inc. boosted its stake in Pfizer by 43.3% in the fourth quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 3,933 shares during the last quarter. ORG Partners LLC grew its holdings in Pfizer by 1,729.9% during the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after acquiring an additional 44,458 shares during the period. Finally, Kempner Capital Management Inc. acquired a new position in shares of Pfizer in the 1st quarter valued at $2,439,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.